Ⅰ. INTRODUCTION Clotting factor Ⅸ is an essential member in the intrinsic clotting pathway, and the deficiency of factor Ⅸ may cause hemophilia B. An important subject on gene therapy for hemophilia B is to increas...Ⅰ. INTRODUCTION Clotting factor Ⅸ is an essential member in the intrinsic clotting pathway, and the deficiency of factor Ⅸ may cause hemophilia B. An important subject on gene therapy for hemophilia B is to increase the protein products of factor Ⅸ in human cells. In our earlier studies, we have constructed several recombinant retroviral vectors with factor展开更多
The human cytomegalovirus (HCMV) major immediate-early (MIE) promoter has strong transcriptional promoting capability. Its cis-acting regulatory elements form a special structure in this region that is repeated multip...The human cytomegalovirus (HCMV) major immediate-early (MIE) promoter has strong transcriptional promoting capability. Its cis-acting regulatory elements form a special structure in this region that is repeated multiple times; the biological significance of these elements and their different compositions in the transcriptional promoting process remain unclear. Our results demonstrate that the HSV-I MIE protein ICP22 can generate strong repression of many viral and cellular promoters and enhancers. We further studied the transcriptional effects of ICP22 on structural elements and mutations in various HCMV MIE promoters by using a CAT assay. In spite of different transcriptional effects of all the ele- ments in the presence of ICP22, the transcriptional efficiencies exhibited by mutations generated by different compositions and an entire HCMV promoter, are not the simple sum of the functions of these elements. Furthermore, the transcriptional activities of specific sequences were not affected by the presence of ICP22. Therefore, it is assumed that the HCMV MIE promoter co-regulates expression of downstream genes by using viral and cellular specific factors via a specific pathway.展开更多
基金This work was supported by a grant from National High Technology Program 863-102-17-40.
文摘Ⅰ. INTRODUCTION Clotting factor Ⅸ is an essential member in the intrinsic clotting pathway, and the deficiency of factor Ⅸ may cause hemophilia B. An important subject on gene therapy for hemophilia B is to increase the protein products of factor Ⅸ in human cells. In our earlier studies, we have constructed several recombinant retroviral vectors with factor
基金the National Natural Science Foundation of China (Grant Nos. 30370065 and 30570081)
文摘The human cytomegalovirus (HCMV) major immediate-early (MIE) promoter has strong transcriptional promoting capability. Its cis-acting regulatory elements form a special structure in this region that is repeated multiple times; the biological significance of these elements and their different compositions in the transcriptional promoting process remain unclear. Our results demonstrate that the HSV-I MIE protein ICP22 can generate strong repression of many viral and cellular promoters and enhancers. We further studied the transcriptional effects of ICP22 on structural elements and mutations in various HCMV MIE promoters by using a CAT assay. In spite of different transcriptional effects of all the ele- ments in the presence of ICP22, the transcriptional efficiencies exhibited by mutations generated by different compositions and an entire HCMV promoter, are not the simple sum of the functions of these elements. Furthermore, the transcriptional activities of specific sequences were not affected by the presence of ICP22. Therefore, it is assumed that the HCMV MIE promoter co-regulates expression of downstream genes by using viral and cellular specific factors via a specific pathway.
